8 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityBody Weight, Nutritional and Metabolic Diseases, Obesity, Abdominal, Overweight, Pathological Conditions, Signs and Symptoms, Prehypertension, Signs and Symptoms, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition, prediabetes syndrome, vascular disorderRecruitingPhase 32026-10-08NCT07794579
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)Chronic Disease, Disease Attributes, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bronchial disorder, bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, pulmonary emphysema, respiratory system disorder, respiratory tract infectious disorderRecruitingPhase 22026-10-08NCT07759245
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)Digestive System Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, Digestive, colonic disorder, constipation disorder, digestive system disorder, functional colonic disease, intestinal disorder, irritable bowel syndromeRecruitingPhase 22026-10-08NCT07545772
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)Digestive System Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, Digestive, colonic disorder, diarrheal disease, digestive system disorder, functional colonic disease, intestinal disorder, irritable bowel syndromeRecruitingPhase 22026-10-08NCT07545759
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe AsthmaHypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorderRecruitingPhase 22026-10-08NCT07219173
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver diseaseRecruitingPhase 32026-10-08NCT07165028
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeBody Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arthritic joint disease, arthropathy, musculoskeletal system disorder, nutritional disorder, obesity disorder, osteoarthritis, overnutrition, rheumatic disorderActive, not recruitingPhase 32026-10-08NCT07153471
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorderRecruitingPhase 32026-09-24NCT07157774